INT-131
INT-131
INT-131 is a selective peroxisome proliferator-activated receptor gamma (PPARγ) modulator that has been investigated for its potential use in the treatment of type 2 diabetes mellitus. Unlike traditional PPARγ agonists, INT-131 is designed to provide the therapeutic benefits of PPARγ activation while minimizing the adverse effects commonly associated with full agonists.
Mechanism of Action[edit | edit source]
INT-131 functions as a selective modulator of the PPARγ receptor, which plays a crucial role in the regulation of glucose and lipid metabolism. By selectively modulating PPARγ, INT-131 aims to enhance insulin sensitivity and improve glycemic control without the side effects such as weight gain and edema that are often seen with full PPARγ agonists like thiazolidinediones.
Clinical Development[edit | edit source]
INT-131 has undergone several phases of clinical trials to evaluate its efficacy and safety in patients with type 2 diabetes. Early studies have shown promising results in terms of improving insulin sensitivity and lowering blood glucose levels. However, further studies are needed to fully establish its long-term safety profile and therapeutic potential.
Potential Benefits[edit | edit source]
The selective modulation of PPARγ by INT-131 offers several potential benefits:
- Improved Insulin Sensitivity: By enhancing the body's response to insulin, INT-131 may help in better management of blood sugar levels.
- Reduced Side Effects: Compared to full PPARγ agonists, INT-131 is expected to have a lower risk of causing weight gain and fluid retention.
- Cardiovascular Safety: Preliminary data suggest that INT-131 may have a favorable cardiovascular safety profile, which is a significant consideration in diabetes management.
Challenges and Considerations[edit | edit source]
While INT-131 shows promise, there are challenges that need to be addressed:
- Long-term Safety: Comprehensive studies are required to assess the long-term safety of INT-131, particularly concerning cardiovascular outcomes.
- Regulatory Approval: As with any new therapeutic agent, INT-131 must undergo rigorous evaluation by regulatory bodies to ensure its efficacy and safety for widespread clinical use.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
